Study to Evaluate SPI-1005 in Adults with Meniere's Disease

To evaluate the safety and efficacy of SPI-1005 compared to placebo in patients with Meniere's.

  1. Tinnitus Talk
    Randomized, double-blind, placebo-controlled safety, pharmacokinetic, pharmacodynamic study of oral SPI-1005 in adults with Meniere's disease. All subjects will undergo baseline audiometric testing and have their severity of sensorineural hearing loss, tinnitus and vertigo determined before the start of a 21-day course of treatment with SPI-1005 or placebo. During treatment with SPI-1005, and 7 days and 28 days following the cessation of SPI-1005, subjects will have their hearing loss, tinnitus and vertigo assessed. Additional testing including electrocochleography will be performed at baseline, at the end of SPI-1005 treatment, and 28 days after the SPI-1005 treatment has stopped. Six outpatient visits will be performed over a 7-week period.

    Estimated Enrollment: 40
    Study Start Date: December 2015
    Estimated Study Completion Date: December 2016
    Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)